All In Biotech

Drug Trial Radar · NCT06176768

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3972406 in Adults With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

33

Actual

Start

Dec 6, 2023

Primary completion

Apr 1, 2025

Study completion May 6, 2025

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Dec 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • LY3972406Drug

    Administered orally

  • PlaceboDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)Time frame: Week 12

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Dermatology Research Associates

    Los Angeles, California

  • Clinical Science Institute

    Santa Monica, California

  • Driven Research

    Coral Gables, Florida

  • Conquest Research

    Winter Park, Florida

  • Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey

  • Schweiger Dermatology Group

    Hackensack, New Jersey

  • Metropolitan Dermatology - Clark

    Kenilworth, New Jersey

  • Accellacare - Winston-Salem

    Winston-Salem, North Carolina

  • Remington-Davis, Inc

    Columbus, Ohio

  • DermDox Centers for Dermatology

    Camp Hill, Pennsylvania

  • Center for Clinical Studies

    Houston, Texas

  • Austin Institute for Clinical Research

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.